Jeng-You Wu, MD, MBA

Taipei Municipal WanFang Hospital
Taipei, Taipei






















































































PUBLICATION





Sarcopenia as an Independent Prognostic Factor for Neoadjuvant Chemoradiation Efficacy in Locally Advanced Rectal Cancer: A Retrospective Analysis



2024 ASTRO Poster presentation





Prediction models of locally advanced rectal cancer prognosis incorporating perioperative longitudinal clinical data: A retrospective longitudinal cohort study.



2024 ASCO Online publication





Enhancing Nasopharyngeal Carcinoma Survival Prediction: Integrating Pre- and Post-Treatment MRI Radiomics with Clinical Data



J Imaging Inform Med. 2024 Apr 30. Epub ahead of print





Deep learning prediction model for CVA in patient with NPC after completing CCRT



2024 ESTRO Poster presentation





Cross-sectional Muscle Area Change in Head and Neck Magnetic Resonance Imaging Defined Sarcopenic State and Survival in Nasopharyngeal Cancer Patients



2023 ASTRO Poster presentation





A multicenter real-world study reviewing relevance between CCRT and CVA for NPC: In the IMRT era



2023 ESTRO Poster presentation





Master Thesis: The Real-World Survival Analysis of Nasopharyngeal Carcinoma in Taipei Medical University Clinical Research Database (TMUCRD)







Retrospective Analysis for Dose Reduction to Organs at Risk with New Personalized Breast Holder (PERSBRA) in Left Breast IMRT



J Pers Med. 2022 Aug 25;12(9):1368.





Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma



Eur J Cancer. 2022 May;166:208-218. Epub 2022 Mar 17.





Chemo-radiotherapy for olfactory neuroblastoma: cases report and literature review



Therapeut Radiol Oncol, Vol 3 (July 2019)





Sarcopenia is associated with inferior response to neoadjuvant chemoradiation in patients with locally advanced rectal cancer



2018 ASTRO Poster presentation





Disclosures:

  • Employment: none
  • Compensation: none
  • Ownership: none
  • Leadership: none